MiniMed reports strong first quarter results with 17% net sales increase

MiniMed, a global leader in diabetes technology, announced robust financial results for the first quarter of fiscal year 2027, marking a significant start to its fiscal year. The company reported net sales of $843 million, a 17% increase from the previous year, with organic growth at 16%. Notably, U.S. net sales grew by 13%, while international sales surged by 18%, driven by the launch of new products and capacity expansions.

"We delivered an excellent start to our fiscal year, with U.S. growth accelerating and continued robust international sales," said Que Dallara, CEO of MiniMed. "The launch of MiniMed Flex™ in the U.S. is driving new patient adoption, generating significant account growth, and reinforcing our leadership in automated insulin delivery."

Key financial highlights include: - Worldwide net sales of $843 million, up 16.6% from the previous year, with organic growth of 15.8% - International net sales of $603 million, a 18.1% increase from the previous year, attributed to Simplera™ capacity expansion and the launch of the Instinct sensor by Abbott - U.S. net sales of $240 million, a 13.1% increase from the previous year, with U.S. New Pumps Sold (NPS) growing over 20% year over year, driven by MiniMed Flex™ and new sensor launches

The company's innovation pipeline is also advancing ahead of schedule: - MiniMed Fit™ patch pump was submitted to the U.S. FDA ahead of the fall target, with a full U.S. launch expected in Summer 2027 - MiniMed Flex™ received a CE Mark, well ahead of the calendar 2026 year-end target, and is set for commercial launch in November - The Vivera™ fully-closed loop algorithm completed U.S. pivotal trial enrollment for both Type 1 and Type 2 diabetes, with a U.S. launch targeted for the second half of 2027 - Next-gen MiniMed extended wear sensor received U.S. IDE approval, with first enrollment in the pivotal trial planned for this fall

Looking ahead, MiniMed expects organic revenue growth of approximately 10.5% for fiscal year 2027, including the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27. The company reaffirmed its adjusted EBITDA margin guidance at approximately 16%.

"Our strong start to the fiscal year reflects our commitment to innovation and the continued growth of our global ecosystem," said Dallara. "We are well-positioned to build on this momentum and deliver on our mission to support people with diabetes in managing their condition."